Last updated: 17 October 2022 at 4:48pm EST

Ventures Fund Iv General Pa... Net Worth




The estimated Net Worth of Ventures Fund Iv General Pa... is at least $14 Milion dollars as of 13 October 2022. Ventures Pa owns over 10,383,760 units of Axcella Health Inc stock worth over $13,963,412 and over the last 4 years Ventures sold AXLA stock worth over $0.

Ventures Pa AXLA stock SEC Form 4 insiders trading

Ventures has made over 2 trades of the Axcella Health Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Ventures bought 10,383,760 units of AXLA stock worth $17,029,366 on 13 October 2022.

The largest trade Ventures's ever made was buying 10,383,760 units of Axcella Health Inc stock on 13 October 2022 worth over $17,029,366. On average, Ventures trades about 6,191,880 units every 431 days since 2020. As of 13 October 2022 Ventures still owns at least 3,048,780 units of Axcella Health Inc stock.

You can see the complete history of Ventures Pa stock trades at the bottom of the page.



Insiders trading at Axcella Health Inc

Over the last 6 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa... a Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.



What does Axcella Health Inc do?

axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.



Complete history of Ventures Pa stock trades at Kaleido Biosciences Inc a Axcella Health Inc

Osoba
Trans.
Transakce
Celková cena
Ventures Fund Iv General Pa...
Koupě $17,029,366
13 Oct 2022
Ventures Fund Iv General Pa...
Koupě $15,000,000
4 Jun 2020


Axcella Health Inc executives and stock owners

Axcella Health Inc executives and other stock owners filed with the SEC include: